{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T22:05:12Z","timestamp":1790546712967,"version":"4.1.0"},"reference-count":88,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2019,7,11]],"date-time":"2019-07-11T00:00:00Z","timestamp":1562803200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2019,7,11]],"date-time":"2019-07-11T00:00:00Z","timestamp":1562803200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"name":"Ministry of Culture and Science Northrine-Westfalia","award":["Nachwuchsgruppen.NRW"],"award-info":[{"award-number":["Nachwuchsgruppen.NRW"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pediatr Nephrol"],"published-print":{"date-parts":[[2020,7]]},"DOI":"10.1007\/s00467-019-04299-3","type":"journal-article","created":{"date-parts":[[2019,7,11]],"date-time":"2019-07-11T17:02:35Z","timestamp":1562864555000},"page":"1143-1152","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":24,"title":["Hippo signaling\u2014a central player in cystic kidney disease?"],"prefix":"10.1007","volume":"35","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6910-0745","authenticated-orcid":false,"given":"Roman-Ulrich","family":"M\u00fcller","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bernhard","family":"Schermer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,7,11]]},"reference":[{"key":"4299_CR1","doi-asserted-by":"publisher","first-page":"781","DOI":"10.1101\/gad.315127.118","volume":"32","author":"J Cai","year":"2018","unstructured":"Cai J, Song X, Wang W, Watnick T, Pei Y, Qian F, Pan D (2018) A RhoA-YAP-c-Myc signaling axis promotes the development of polycystic kidney disease. Genes Dev 32:781\u2013793. https:\/\/doi.org\/10.1101\/gad.315127.118","journal-title":"Genes Dev"},{"key":"4299_CR2","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1002\/path.2856","volume":"224","author":"H Happ\u00e9","year":"2011","unstructured":"Happ\u00e9 H, van der Wal AM, Leonhard WN, Kunnen SJ, Breuning MH, de Heer E, Peters DJM (2011) Altered Hippo signaling in polycystic kidney disease. J Pathol 224:133\u2013142. https:\/\/doi.org\/10.1002\/path.2856","journal-title":"J Pathol"},{"key":"4299_CR3","doi-asserted-by":"publisher","first-page":"1631","DOI":"10.1073\/pnas.0605266104","volume":"104","author":"Z Hossain","year":"2007","unstructured":"Hossain Z, Ali SM, Ko HL, Xu J, Ng CP, Guo K, Qi Z, Ponniah S, Hong W, Hunziker W (2007) Glomerulocystic kidney disease in mice with a targeted inactivation of Wwtr1. Proc Natl Acad Sci U S A 104:1631\u20131636. https:\/\/doi.org\/10.1073\/pnas.0605266104","journal-title":"Proc Natl Acad Sci U S A"},{"key":"4299_CR4","doi-asserted-by":"publisher","first-page":"e1003380","DOI":"10.1371\/journal.pgen.1003380","volume":"9","author":"A Reginensi","year":"2013","unstructured":"Reginensi A, Scott RP, Gregorieff A, Bagherie-Lachidan M, Chung C, Lim D-S, Pawson T, Wrana J, McNeill H (2013) Yap- and Cdc42-dependent nephrogenesis and morphogenesis during mouse kidney development. PLoS Genet 9:e1003380. https:\/\/doi.org\/10.1371\/journal.pgen.1003380","journal-title":"PLoS Genet"},{"key":"4299_CR5","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1002\/path.4706","volume":"239","author":"T Kai","year":"2016","unstructured":"Kai T, Tsukamoto Y, Hijiya N, Tokunaga A, Nakada C, Uchida T, Daa T, Iha H, Takahashi M, Nomura T, Sato F, Mimata H, Ikawa M, Seto M, Matsuura K, Moriyama M (2016) Kidney-specific knockout of Sav1 in the mouse promotes hyperproliferation of renal tubular epithelium through suppression of the Hippo pathway. J Pathol 239:97\u2013108. https:\/\/doi.org\/10.1002\/path.4706","journal-title":"J Pathol"},{"key":"4299_CR6","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1007\/978-1-4939-8910-2_1","volume":"1893","author":"R Gokhale","year":"2019","unstructured":"Gokhale R, Pfleger CM (2019) The power of Drosophila genetics: the discovery of the Hippo pathway. Methods Mol Biol 1893:3\u201326. https:\/\/doi.org\/10.1007\/978-1-4939-8910-2_1","journal-title":"Methods Mol Biol"},{"key":"4299_CR7","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1038\/s41580-018-0086-y","volume":"20","author":"IM Moya","year":"2019","unstructured":"Moya IM, Halder G (2019) Hippo-YAP\/TAZ signaling in organ regeneration and regenerative medicine. Nat Rev Mol Cell Biol 20:211\u2013226. https:\/\/doi.org\/10.1038\/s41580-018-0086-y","journal-title":"Nat Rev Mol Cell Biol"},{"issue":"1","key":"4299_CR8","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1146\/annurev-biochem-013118-111829","volume":"88","author":"Shenghong Ma","year":"2019","unstructured":"Ma S, Meng Z, Chen R, Guan K-L (2018) The hippo pathway: biology and pathophysiology. Annu Rev Biochem. https:\/\/doi.org\/10.1146\/annurev-biochem-013118-111829","journal-title":"Annual Review of Biochemistry"},{"key":"4299_CR9","doi-asserted-by":"publisher","first-page":"836","DOI":"10.1038\/nrm1489","volume":"5","author":"R Taub","year":"2004","unstructured":"Taub R (2004) Liver regeneration: from myth to mechanism. Nat Rev Mol Cell Biol 5:836\u2013847. https:\/\/doi.org\/10.1038\/nrm1489","journal-title":"Nat Rev Mol Cell Biol"},{"key":"4299_CR10","doi-asserted-by":"publisher","first-page":"33","DOI":"10.3389\/fcell.2019.00033","volume":"7","author":"S Manmadhan","year":"2019","unstructured":"Manmadhan S, Ehmer U (2019) Hippo signaling in the liver - a long and ever-expanding story. Front Cell Dev Biol 7:33. https:\/\/doi.org\/10.3389\/fcell.2019.00033","journal-title":"Front Cell Dev Biol"},{"key":"4299_CR11","doi-asserted-by":"publisher","first-page":"534","DOI":"10.1101\/gad.9.5.534","volume":"9","author":"RW Justice","year":"1995","unstructured":"Justice RW, Zilian O, Woods DF, Noll M, Bryant PJ (1995) The Drosophila tumor suppressor gene warts encodes a homolog of human myotonic dystrophy kinase and is required for the control of cell shape and proliferation. Genes Dev 9:534\u2013546","journal-title":"Genes Dev"},{"key":"4299_CR12","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1242\/dev.121.4.1053","volume":"121","author":"T Xu","year":"1995","unstructured":"Xu T, Wang W, Zhang S, Stewart RA, Yu W (1995) Identifying tumor suppressors in genetic mosaics: the Drosophila lats gene encodes a putative protein kinase. Development 121:1053\u20131063","journal-title":"Development"},{"key":"4299_CR13","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1016\/S0092-8674(02)00824-3","volume":"110","author":"N Tapon","year":"2002","unstructured":"Tapon N, Harvey KF, Bell DW, Wahrer DCR, Schiripo TA, Haber DA, Hariharan IK (2002) salvador Promotes both cell cycle exit and apoptosis in Drosophila and is mutated in human cancer cell lines. Cell 110:467\u2013478","journal-title":"Cell"},{"key":"4299_CR14","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1016\/S0092-8674(03)00557-9","volume":"114","author":"KF Harvey","year":"2003","unstructured":"Harvey KF, Pfleger CM, Hariharan IK (2003) The Drosophila Mst ortholog, hippo, restricts growth and cell proliferation and promotes apoptosis. Cell 114:457\u2013467","journal-title":"Cell"},{"key":"4299_CR15","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1016\/S0092-8674(03)00549-X","volume":"114","author":"S Wu","year":"2003","unstructured":"Wu S, Huang J, Dong J, Pan D (2003) Hippo encodes a Ste-20 family protein kinase that restricts cell proliferation and promotes apoptosis in conjunction with salvador and warts. Cell 114:445\u2013456","journal-title":"Cell"},{"key":"4299_CR16","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1016\/j.cell.2005.06.007","volume":"122","author":"J Huang","year":"2005","unstructured":"Huang J, Wu S, Barrera J, Matthews K, Pan D (2005) The Hippo signaling pathway coordinately regulates cell proliferation and apoptosis by inactivating Yorkie, the Drosophila homolog of YAP. Cell 122:421\u2013434. https:\/\/doi.org\/10.1016\/j.cell.2005.06.007","journal-title":"Cell"},{"key":"4299_CR17","doi-asserted-by":"publisher","first-page":"1120","DOI":"10.1016\/j.cell.2007.07.019","volume":"130","author":"J Dong","year":"2007","unstructured":"Dong J, Feldmann G, Huang J, Wu S, Zhang N, Comerford SA, Gayyed MF, Anders RA, Maitra A, Pan D (2007) Elucidation of a universal size-control mechanism in Drosophila and mammals. Cell 130:1120\u20131133. https:\/\/doi.org\/10.1016\/j.cell.2007.07.019","journal-title":"Cell"},{"issue":"11","key":"4299_CR18","doi-asserted-by":"publisher","first-page":"449","DOI":"10.3390\/cancers10110449","volume":"10","author":"Xinyan Ji","year":"2018","unstructured":"Ji X, Song L, Sheng L, Gao A, Zhao Y, Han S, Zhang Y, Zhu C, Zhao S, Wang Z, Xu B, Li L, Li J, Tan N, Zhao B (2018) Cyclopeptide RA-V inhibits organ enlargement and tumorigenesis induced by YAP activation. Cancers (Basel) 10. https:\/\/doi.org\/10.3390\/cancers10110449","journal-title":"Cancers"},{"key":"4299_CR19","first-page":"27","volume":"6","author":"C Wang","year":"2016","unstructured":"Wang C, Zhu X, Feng W, Yu Y, Jeong K, Guo W, Lu Y, Mills GB (2016) Verteporfin inhibits YAP function through up-regulating 14-3-3\u03c3 sequestering YAP in the cytoplasm. Am J Cancer Res 6:27\u201337","journal-title":"Am J Cancer Res"},{"key":"4299_CR20","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1111\/bju.14638","volume":"123","author":"U Milenkovic","year":"2019","unstructured":"Milenkovic U, Ilg MM, Zuccato C, Ramazani Y, De Ridder D, Albersen M (2019) Simvastatin and the Rho-kinase inhibitor Y-27632 prevent myofibroblast transformation in Peyronie\u2019s disease-derived fibroblasts via inhibition of YAP\/TAZ nuclear translocation. BJU Int 123:703\u2013715. https:\/\/doi.org\/10.1111\/bju.14638","journal-title":"BJU Int"},{"issue":"4","key":"4299_CR21","doi-asserted-by":"publisher","first-page":"736","DOI":"10.1016\/j.bbrc.2019.03.158","volume":"512","author":"Pei Wu","year":"2019","unstructured":"Wu P, Liu Z, Zhao T, Xia F, Gong L, Zheng Z, Chen Z, Yang T, Duan Q (2019) Lovastatin attenuates angiotensin II induced cardiovascular fibrosis through the suppression of YAP\/TAZ signaling. Biochem Biophys Res Commun. https:\/\/doi.org\/10.1016\/j.bbrc.2019.03.158","journal-title":"Biochemical and Biophysical Research Communications"},{"key":"4299_CR22","doi-asserted-by":"publisher","first-page":"993","DOI":"10.1021\/ml500160m","volume":"5","author":"Z Zhang","year":"2014","unstructured":"Zhang Z, Lin Z, Zhou Z, Shen HC, Yan SF, Mayweg AV, Xu Z, Qin N, Wong JC, Zhang Z, Rong Y, Fry DC, Hu T (2014) Structure-based design and synthesis of potent cyclic peptides inhibiting the YAP-TEAD protein-protein interaction. ACS Med Chem Lett 5:993\u2013998. https:\/\/doi.org\/10.1021\/ml500160m","journal-title":"ACS Med Chem Lett"},{"key":"4299_CR23","doi-asserted-by":"publisher","first-page":"724","DOI":"10.1096\/fj.14-262980","volume":"29","author":"Z Zhou","year":"2015","unstructured":"Zhou Z, Hu T, Xu Z, Lin Z, Zhang Z, Feng T, Zhu L, Rong T, Shen H, Luk JM, Zhang X, Qin N (2015) Targeting Hippo pathway by specific interruption of YAP-TEAD interaction using cyclic YAP-like peptides. FASEB J 29:724\u2013732. https:\/\/doi.org\/10.1096\/fj.14-262980","journal-title":"FASEB J"},{"key":"4299_CR24","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1016\/j.tcb.2015.05.002","volume":"25","author":"CG Hansen","year":"2015","unstructured":"Hansen CG, Moroishi T, Guan K-L (2015) YAP and TAZ: a nexus for Hippo signaling and beyond. Trends Cell Biol 25:499\u2013513. https:\/\/doi.org\/10.1016\/j.tcb.2015.05.002","journal-title":"Trends Cell Biol"},{"key":"4299_CR25","doi-asserted-by":"publisher","first-page":"i2","DOI":"10.1093\/ckj\/sfy103","volume":"11","author":"R-U M\u00fcller","year":"2018","unstructured":"M\u00fcller R-U, Benzing T (2018) Management of autosomal-dominant polycystic kidney disease\u2014state-of-the-art. Clin Kidney J 11:i2\u2013i13. https:\/\/doi.org\/10.1093\/ckj\/sfy103","journal-title":"Clin Kidney J"},{"key":"4299_CR26","doi-asserted-by":"publisher","first-page":"888","DOI":"10.1038\/s41556-018-0142-z","volume":"20","author":"A Totaro","year":"2018","unstructured":"Totaro A, Panciera T, Piccolo S (2018) YAP\/TAZ upstream signals and downstream responses. Nat Cell Biol 20:888\u2013899. https:\/\/doi.org\/10.1038\/s41556-018-0142-z","journal-title":"Nat Cell Biol"},{"key":"4299_CR27","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1136\/jmedgenet-2015-103304","volume":"53","author":"M Schueler","year":"2016","unstructured":"Schueler M, Halbritter J, Phelps IG, Braun DA, Otto EA, Porath JD, Gee HY, Shendure J, O\u2019Roak BJ, Lawson JA, Nabhan MM, Soliman NA, Doherty D, Hildebrandt F (2016) Large-scale targeted sequencing comparison highlights extreme genetic heterogeneity in nephronophthisis-related ciliopathies. J Med Genet 53:208\u2013214. https:\/\/doi.org\/10.1136\/jmedgenet-2015-103304","journal-title":"J Med Genet"},{"key":"4299_CR28","doi-asserted-by":"publisher","first-page":"5370","DOI":"10.1038\/ncomms6370","volume":"5","author":"M Kim","year":"2014","unstructured":"Kim M, Kim M, Lee M-S, Kim C-H, Lim D-S (2014) The MST1\/2-SAV1 complex of the Hippo pathway promotes ciliogenesis. Nat Commun 5:5370. https:\/\/doi.org\/10.1038\/ncomms6370","journal-title":"Nat Commun"},{"key":"4299_CR29","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1083\/jcb.201009069","volume":"193","author":"S Habbig","year":"2011","unstructured":"Habbig S, Bartram MP, M\u00fcller RU, Schwarz R, Andriopoulos N, Chen S, S\u00e4gm\u00fcller JG, Hoehne M, Burst V, Liebau MC, Reinhardt HC, Benzing T, Schermer B (2011) NPHP4, a cilia-associated protein, negatively regulates the Hippo pathway. J Cell Biol 193:633\u2013642. https:\/\/doi.org\/10.1083\/jcb.201009069","journal-title":"J Cell Biol"},{"key":"4299_CR30","doi-asserted-by":"publisher","first-page":"5528","DOI":"10.1093\/hmg\/dds408","volume":"21","author":"S Habbig","year":"2012","unstructured":"Habbig S, Bartram MP, S\u00e4gm\u00fcller JG, Griessmann A, Franke M, M\u00fcller R-U, Schwarz R, Hoehne M, Bergmann C, Tessmer C, Reinhardt HC, Burst V, Benzing T, Schermer B (2012) The ciliopathy disease protein NPHP9 promotes nuclear delivery and activation of the oncogenic transcriptional regulator TAZ. Hum Mol Genet 21:5528\u20135538. https:\/\/doi.org\/10.1093\/hmg\/dds408","journal-title":"Hum Mol Genet"},{"key":"4299_CR31","doi-asserted-by":"publisher","first-page":"6383","DOI":"10.1128\/MCB.00254-07","volume":"27","author":"Y Tian","year":"2007","unstructured":"Tian Y, Kolb R, Hong J-H, Carroll J, Li D, You J, Bronson R, Yaffe MB, Zhou J, Benjamin T (2007) TAZ promotes PC2 degradation through a SCFbeta-Trcp E3 ligase complex. Mol Cell Biol 27:6383\u20136395. https:\/\/doi.org\/10.1128\/MCB.00254-07","journal-title":"Mol Cell Biol"},{"key":"4299_CR32","doi-asserted-by":"publisher","first-page":"1472","DOI":"10.1093\/ndt\/gfs551","volume":"28","author":"HPH Neumann","year":"2013","unstructured":"Neumann HPH, Jilg C, Bacher J, Nabulsi Z, Malinoc A, Hummel B, Hoffmann MM, Ortiz-Bruechle N, Glasker S, Pisarski P, Neeff H, Kr\u00e4mer-Guth A, Cybulla M, Hornberger M, Wilpert J, Funk L, Baumert J, Paatz D, Baumann D, Lahl M, Felten H, Hausberg M, Zerres K, Eng C, Else-Kroener-Fresenius-ADPKD-Registry (2013) Epidemiology of autosomal-dominant polycystic kidney disease: an in-depth clinical study for south-western Germany. Nephrol Dial Transplant 28:1472\u20131487. https:\/\/doi.org\/10.1093\/ndt\/gfs551","journal-title":"Nephrol Dial Transplant"},{"key":"4299_CR33","doi-asserted-by":"publisher","first-page":"2044","DOI":"10.1093\/ndt\/gfh317","volume":"19","author":"K Wakai","year":"2004","unstructured":"Wakai K, Nakai S, Kikuchi K, Iseki K, Miwa N, Masakane I, Wada A, Shinzato T, Nagura Y, Akiba T (2004) Trends in incidence of end-stage renal disease in Japan, 1983-2000: age-adjusted and age-specific rates by gender and cause. Nephrol Dial Transplant 19:2044\u20132052. https:\/\/doi.org\/10.1093\/ndt\/gfh317","journal-title":"Nephrol Dial Transplant"},{"key":"4299_CR34","doi-asserted-by":"publisher","first-page":"1824","DOI":"10.1093\/ndt\/gfg233","volume":"18","author":"B Stengel","year":"2003","unstructured":"Stengel B, Billon S, Van Dijk PCW, Jager KJ, Dekker FW, Simpson K, Briggs JD (2003) Trends in the incidence of renal replacement therapy for end-stage renal disease in Europe, 1990-1999. Nephrol Dial Transplant 18:1824\u20131833","journal-title":"Nephrol Dial Transplant"},{"key":"4299_CR35","doi-asserted-by":"publisher","first-page":"2593","DOI":"10.1681\/ASN.2018050493","volume":"29","author":"MB Lanktree","year":"2018","unstructured":"Lanktree MB, Haghighi A, Guiard E, Iliuta IA, Song X, Harris PC, Paterson AD, Pei Y (2018) Prevalence estimates of polycystic kidney and liver disease by population sequencing. J Am Soc Nephrol 29:2593\u20132600. https:\/\/doi.org\/10.1681\/ASN.2018050493","journal-title":"J Am Soc Nephrol"},{"key":"4299_CR36","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/j.ceca.2017.05.011","volume":"69","author":"FO Lemos","year":"2018","unstructured":"Lemos FO, Ehrlich BE (2018) Polycystin and calcium signaling in cell death and survival. Cell Calcium 69:37\u201345. https:\/\/doi.org\/10.1016\/j.ceca.2017.05.011","journal-title":"Cell Calcium"},{"issue":"5","key":"4299_CR37","doi-asserted-by":"publisher","first-page":"6894","DOI":"10.1002\/jcb.28127","volume":"120","author":"Antonios N. Gargalionis","year":"2018","unstructured":"Gargalionis AN, Basdra EK, Papavassiliou AG (2018) Polycystins in disease mechanobiology. J Cell Biochem. https:\/\/doi.org\/10.1002\/jcb.28127","journal-title":"Journal of Cellular Biochemistry"},{"key":"4299_CR38","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1038\/s41572-018-0047-y","volume":"4","author":"C Bergmann","year":"2018","unstructured":"Bergmann C, Guay-Woodford LM, Harris PC, Horie S, Peters DJM, Torres VE (2018) Polycystic kidney disease. Nat Rev Dis Primers 4:50. https:\/\/doi.org\/10.1038\/s41572-018-0047-y","journal-title":"Nat Rev Dis Primers"},{"issue":"11","key":"4299_CR39","doi-asserted-by":"publisher","first-page":"1765","DOI":"10.2215\/CJN.03960318","volume":"13","author":"Fouad T. Chebib","year":"2018","unstructured":"Chebib FT, Torres VE (2018) Recent advances in the management of autosomal dominant polycystic kidney disease. Clin J Am Soc Nephrol. https:\/\/doi.org\/10.2215\/CJN.03960318","journal-title":"Clinical Journal of the American Society of Nephrology"},{"key":"4299_CR40","doi-asserted-by":"publisher","first-page":"i27","DOI":"10.1093\/ckj\/sfy089","volume":"11","author":"T Weimbs","year":"2018","unstructured":"Weimbs T, Shillingford JM, Torres J, Kruger SL, Bourgeois BC (2018) Emerging targeted strategies for the treatment of autosomal dominant polycystic kidney disease. Clin Kidney J 11:i27\u2013i38. https:\/\/doi.org\/10.1093\/ckj\/sfy089","journal-title":"Clin Kidney J"},{"key":"4299_CR41","doi-asserted-by":"publisher","first-page":"832","DOI":"10.1681\/ASN.2010090992","volume":"22","author":"H Yim","year":"2011","unstructured":"Yim H, Sung CK, You J, Tian Y, Benjamin T (2011) Nek1 and TAZ interact to maintain normal levels of polycystin 2. J Am Soc Nephrol 22:832\u2013837. https:\/\/doi.org\/10.1681\/ASN.2010090992","journal-title":"J Am Soc Nephrol"},{"key":"4299_CR42","doi-asserted-by":"publisher","first-page":"31931","DOI":"10.1038\/srep31931","volume":"6","author":"E Seo","year":"2016","unstructured":"Seo E, Kim W-Y, Hur J, Kim H, Nam SA, Choi A, Kim Y-M, Park SH, Chung C, Kim J, Min S, Myung S-J, Lim D-S, Kim YK (2016) The Hippo-Salvador signaling pathway regulates renal tubulointerstitial fibrosis. Sci Rep 6:31931. https:\/\/doi.org\/10.1038\/srep31931","journal-title":"Sci Rep"},{"key":"4299_CR43","doi-asserted-by":"publisher","first-page":"3117","DOI":"10.1681\/ASN.2015050499","volume":"27","author":"SG Szeto","year":"2016","unstructured":"Szeto SG, Narimatsu M, Lu M, He X, Sidiqi AM, Tolosa MF, Chan L, De Freitas K, Bialik JF, Majumder S, Boo S, Hinz B, Dan Q, Advani A, John R, Wrana JL, Kapus A, Yuen DA (2016) YAP\/TAZ are Mechanoregulators of TGF-\u03b2-Smad signaling and renal fibrogenesis. J Am Soc Nephrol 27:3117\u20133128. https:\/\/doi.org\/10.1681\/ASN.2015050499","journal-title":"J Am Soc Nephrol"},{"key":"4299_CR44","doi-asserted-by":"publisher","first-page":"19290","DOI":"10.1074\/jbc.RA118.005457","volume":"293","author":"Y Feng","year":"2018","unstructured":"Feng Y, Liang Y, Zhu X, Wang M, Gui Y, Lu Q, Gu M, Xue X, Sun X, He W, Yang J, Johnson RL, Dai C (2018) The signaling protein Wnt5a promotes TGF\u03b21-mediated macrophage polarization and kidney fibrosis by inducing the transcriptional regulators Yap\/Taz. J Biol Chem 293:19290\u201319302. https:\/\/doi.org\/10.1074\/jbc.RA118.005457","journal-title":"J Biol Chem"},{"key":"4299_CR45","doi-asserted-by":"publisher","first-page":"4323","DOI":"10.1038\/s41598-019-40764-7","volume":"9","author":"JF Bialik","year":"2019","unstructured":"Bialik JF, Ding M, Speight P, Dan Q, Miranda MZ, Di Ciano-Oliveira C, Kofler MM, Rotstein OD, Pedersen SF, Sz\u00e1szi K, Kapus A (2019) Profibrotic epithelial phenotype: a central role for MRTF and TAZ. Sci Rep 9:4323. https:\/\/doi.org\/10.1038\/s41598-019-40764-7","journal-title":"Sci Rep"},{"key":"4299_CR46","doi-asserted-by":"publisher","first-page":"16364","DOI":"10.1074\/jbc.RA118.004073","volume":"293","author":"Y Gui","year":"2018","unstructured":"Gui Y, Li J, Lu Q, Feng Y, Wang M, He W, Yang J, Dai C (2018) Yap\/Taz mediates mTORC2-stimulated fibroblast activation and kidney fibrosis. J Biol Chem 293:16364\u201316375. https:\/\/doi.org\/10.1074\/jbc.RA118.004073","journal-title":"J Biol Chem"},{"key":"4299_CR47","doi-asserted-by":"publisher","first-page":"2644","DOI":"10.1096\/fj.201700722R","volume":"32","author":"S Anorga","year":"2018","unstructured":"Anorga S, Overstreet JM, Falke LL, Tang J, Goldschmeding RG, Higgins PJ, Samarakoon R (2018) Deregulation of Hippo-TAZ pathway during renal injury confers a fibrotic maladaptive phenotype. FASEB J 32:2644\u20132657. https:\/\/doi.org\/10.1096\/fj.201700722R","journal-title":"FASEB J"},{"key":"4299_CR48","doi-asserted-by":"publisher","first-page":"3278","DOI":"10.1681\/ASN.2015121354","volume":"28","author":"M Liang","year":"2017","unstructured":"Liang M, Yu M, Xia R, Song K, Wang J, Luo J, Chen G, Cheng J (2017) Yap\/Taz deletion in Gli+ cell-derived myofibroblasts attenuates fibrosis. J Am Soc Nephrol 28:3278\u20133290. https:\/\/doi.org\/10.1681\/ASN.2015121354","journal-title":"J Am Soc Nephrol"},{"key":"4299_CR49","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1007\/978-3-319-51436-9_12","volume":"60","author":"CJ Song","year":"2017","unstructured":"Song CJ, Zimmerman KA, Henke SJ, Yoder BK (2017) Inflammation and fibrosis in polycystic kidney disease. Results Probl Cell Differ 60:323\u2013344. https:\/\/doi.org\/10.1007\/978-3-319-51436-9_12","journal-title":"Results Probl Cell Differ"},{"key":"4299_CR50","doi-asserted-by":"publisher","first-page":"2005","DOI":"10.1046\/j.1523-1755.2001.00716.x","volume":"59","author":"Q Qian","year":"2001","unstructured":"Qian Q, Harris PC, Torres VE (2001) Treatment prospects for autosomal-dominant polycystic kidney disease. Kidney Int 59:2005\u20132022. https:\/\/doi.org\/10.1046\/j.1523-1755.2001.00716.x","journal-title":"Kidney Int"},{"key":"4299_CR51","doi-asserted-by":"publisher","first-page":"1218","DOI":"10.1038\/ncb3216","volume":"17","author":"F Zanconato","year":"2015","unstructured":"Zanconato F, Forcato M, Battilana G, Azzolin L, Quaranta E, Bodega B, Rosato A, Bicciato S, Cordenonsi M, Piccolo S (2015) Genome-wide association between YAP\/TAZ\/TEAD and AP-1 at enhancers drives oncogenic growth. Nat Cell Biol 17:1218\u20131227. https:\/\/doi.org\/10.1038\/ncb3216","journal-title":"Nat Cell Biol"},{"key":"4299_CR52","doi-asserted-by":"publisher","first-page":"2328","DOI":"10.1093\/hmg\/ddp165","volume":"18","author":"X Song","year":"2009","unstructured":"Song X, Di Giovanni V, He N, Wang K, Ingram A, Rosenblum ND, Pei Y (2009) Systems biology of autosomal dominant polycystic kidney disease (ADPKD): computational identification of gene expression pathways and integrated regulatory networks. Hum Mol Genet 18:2328\u20132343. https:\/\/doi.org\/10.1093\/hmg\/ddp165","journal-title":"Hum Mol Genet"},{"key":"4299_CR53","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1038\/ki.1991.80","volume":"39","author":"M Trudel","year":"1991","unstructured":"Trudel M, D\u2019Agati V, Costantini F (1991) C-myc as an inducer of polycystic kidney disease in transgenic mice. Kidney Int 39:665\u2013671","journal-title":"Kidney Int"},{"key":"4299_CR54","doi-asserted-by":"publisher","first-page":"751","DOI":"10.1093\/hmg\/ddy379","volume":"28","author":"C Parrot","year":"2019","unstructured":"Parrot C, Kurbegovic A, Yao G, Couillard M, C\u00f4t\u00e9 O, Trudel M (2019) C-MYC is a regulator of the PKD1 gene and PC1-induced pathogenesis. Hum Mol Genet 28:751\u2013763. https:\/\/doi.org\/10.1093\/hmg\/ddy379","journal-title":"Hum Mol Genet"},{"key":"4299_CR55","doi-asserted-by":"publisher","first-page":"4394","DOI":"10.1096\/fj.201701376RR","volume":"32","author":"D Xu","year":"2018","unstructured":"Xu D, Lv J, He L, Fu L, Hu R, Cao Y, Mei C (2018) Scribble influences cyst formation in autosomal-dominant polycystic kidney disease by regulating Hippo signaling pathway. FASEB J 32:4394\u20134407. https:\/\/doi.org\/10.1096\/fj.201701376RR","journal-title":"FASEB J"},{"key":"4299_CR56","doi-asserted-by":"publisher","first-page":"8579","DOI":"10.1073\/pnas.0811691106","volume":"106","author":"K Skouloudaki","year":"2009","unstructured":"Skouloudaki K, Puetz M, Simons M, Courbard J-R, Boehlke C, Hartleben B, Engel C, Moeller MJ, Englert C, Bollig F, Sch\u00e4fer T, Ramachandran H, Mlodzik M, Huber TB, Kuehn EW, Kim E, Kramer-Zucker A, Walz G (2009) Scribble participates in Hippo signaling and is required for normal zebrafish pronephros development. Proc Natl Acad Sci U S A 106:8579\u20138584. https:\/\/doi.org\/10.1073\/pnas.0811691106","journal-title":"Proc Natl Acad Sci U S A"},{"key":"4299_CR57","doi-asserted-by":"publisher","first-page":"313","DOI":"10.3727\/105221617X15034976037343","volume":"17","author":"L Jiang","year":"2017","unstructured":"Jiang L, Sun L, Edwards G, Manley M, Wallace DP, Septer S, Manohar C, Pritchard MT, Apte U (2017) Increased YAP activation is associated with hepatic cyst epithelial cell proliferation in ARPKD\/CHF. Gene Expr 17:313\u2013326. https:\/\/doi.org\/10.3727\/105221617X15034976037343","journal-title":"Gene Expr"},{"key":"4299_CR58","doi-asserted-by":"publisher","first-page":"530","DOI":"10.1038\/nrneph.2010.97","volume":"6","author":"A Patel","year":"2010","unstructured":"Patel A, Honor\u00e9 E (2010) Polycystins and renovascular mechanosensory transduction. Nat Rev Nephrol 6:530\u2013538. https:\/\/doi.org\/10.1038\/nrneph.2010.97","journal-title":"Nat Rev Nephrol"},{"key":"4299_CR59","doi-asserted-by":"publisher","first-page":"1015","DOI":"10.1681\/ASN.2005080830","volume":"17","author":"SM Nauli","year":"2006","unstructured":"Nauli SM, Rossetti S, Kolb RJ, Alenghat FJ, Consugar MB, Harris PC, Ingber DE, Loghman-Adham M, Zhou J (2006) Loss of polycystin-1 in human cyst-lining epithelia leads to ciliary dysfunction. J Am Soc Nephrol 17:1015\u20131025. https:\/\/doi.org\/10.1681\/ASN.2005080830","journal-title":"J Am Soc Nephrol"},{"key":"4299_CR60","doi-asserted-by":"publisher","first-page":"888","DOI":"10.1681\/ASN.2013111179","volume":"26","author":"K Lee","year":"2015","unstructured":"Lee K, Boctor S, Barisoni LMC, Gusella GL (2015) Inactivation of integrin-\u03b21 prevents the development of polycystic kidney disease after the loss of polycystin-1. J Am Soc Nephrol 26:888\u2013895. https:\/\/doi.org\/10.1681\/ASN.2013111179","journal-title":"J Am Soc Nephrol"},{"key":"4299_CR61","doi-asserted-by":"publisher","first-page":"3675","DOI":"10.1242\/jcs.190496","volume":"129","author":"Y Wu","year":"2016","unstructured":"Wu Y, Xu JX, El-Jouni W, Lu T, Li S, Wang Q, Tran M, Yu W, Wu M, Barrera IE, Bonventre JV, Zhou J, Denker BM, Kong T (2016) G\u03b112 is required for renal cystogenesis induced by Pkd1 inactivation. J Cell Sci 129:3675\u20133684. https:\/\/doi.org\/10.1242\/jcs.190496","journal-title":"J Cell Sci"},{"key":"4299_CR62","doi-asserted-by":"publisher","first-page":"1262","DOI":"10.1093\/ndt\/gfx079","volume":"32","author":"VE Torres","year":"2017","unstructured":"Torres VE, Chapman AB, Devuyst O, Gansevoort RT, Perrone RD, Dandurand A, Ouyang J, Czerwiec FS, Blais JD, TEMPO 4:4 Trial Investigators (2017) Multicenter, open-label, extension trial to evaluate the long-term efficacy and safety of early versus delayed treatment with tolvaptan in autosomal dominant polycystic kidney disease: the TEMPO 4:4 Trial. Nephrol Dial Transplant 32:1262. https:\/\/doi.org\/10.1093\/ndt\/gfx079","journal-title":"Nephrol Dial Transplant"},{"key":"4299_CR63","doi-asserted-by":"publisher","first-page":"1930","DOI":"10.1056\/NEJMoa1710030","volume":"377","author":"VE Torres","year":"2017","unstructured":"Torres VE, Chapman AB, Devuyst O, Gansevoort RT, Perrone RD, Koch G, Ouyang J, McQuade RD, Blais JD, Czerwiec FS, Sergeyeva O, Trial Investigators REPRISE (2017) Tolvaptan in later-stage autosomal dominant polycystic kidney disease. N Engl J Med 377:1930\u20131942. https:\/\/doi.org\/10.1056\/NEJMoa1710030","journal-title":"N Engl J Med"},{"key":"4299_CR64","doi-asserted-by":"publisher","first-page":"2407","DOI":"10.1056\/NEJMoa1205511","volume":"367","author":"VE Torres","year":"2012","unstructured":"Torres VE, Chapman AB, Devuyst O, Gansevoort RT, Grantham JJ, Higashihara E, Perrone RD, Krasa HB, Ouyang J, Czerwiec FS (2012) Tolvaptan in patients with autosomal dominant polycystic kidney disease. N Engl J Med 367:2407\u20132418. https:\/\/doi.org\/10.1056\/NEJMoa1205511","journal-title":"N Engl J Med"},{"key":"4299_CR65","doi-asserted-by":"publisher","first-page":"1103","DOI":"10.1007\/s40264-015-0327-3","volume":"38","author":"PB Watkins","year":"2015","unstructured":"Watkins PB, Lewis JH, Kaplowitz N, Alpers DH, Blais JD, Smotzer DM, Krasa H, Ouyang J, Torres VE, Czerwiec FS, Zimmer CA (2015) Clinical pattern of tolvaptan-associated liver injury in subjects with autosomal dominant polycystic kidney disease: analysis of clinical trials database. Drug Saf 38:1103\u20131113. https:\/\/doi.org\/10.1007\/s40264-015-0327-3","journal-title":"Drug Saf"},{"key":"4299_CR66","doi-asserted-by":"publisher","first-page":"1300","DOI":"10.1101\/gad.192856.112","volume":"26","author":"Y Liu-Chittenden","year":"2012","unstructured":"Liu-Chittenden Y, Huang B, Shim JS, Chen Q, Lee S-J, Anders RA, Liu JO, Pan D (2012) Genetic and pharmacological disruption of the TEAD\u2013YAP complex suppresses the oncogenic activity of YAP. Genes Dev 26:1300\u20131305. https:\/\/doi.org\/10.1101\/gad.192856.112","journal-title":"Genes Dev"},{"key":"4299_CR67","doi-asserted-by":"publisher","first-page":"2372","DOI":"10.1681\/ASN.2017121272","volume":"29","author":"J Chen","year":"2018","unstructured":"Chen J, You H, Li Y, Xu Y, He Q, Harris RC (2018) EGF receptor-dependent YAP activation is important for renal recovery from AKI. J Am Soc Nephrol 29:2372\u20132385. https:\/\/doi.org\/10.1681\/ASN.2017121272","journal-title":"J Am Soc Nephrol"},{"key":"4299_CR68","doi-asserted-by":"publisher","first-page":"5371","DOI":"10.2147\/OTT.S109979","volume":"9","author":"J Feng","year":"2016","unstructured":"Feng J, Gou J, Jia J, Yi T, Cui T, Li Z (2016) Verteporfin, a suppressor of YAP-TEAD complex, presents promising antitumor properties on ovarian cancer. Onco Targets Ther 9:5371\u20135381. https:\/\/doi.org\/10.2147\/OTT.S109979","journal-title":"Onco Targets Ther"},{"key":"4299_CR69","doi-asserted-by":"publisher","first-page":"478","DOI":"10.1111\/cas.13138","volume":"108","author":"H Wei","year":"2017","unstructured":"Wei H, Wang F, Wang Y, Li T, Xiu P, Zhong J, Sun X, Li J (2017) Verteporfin suppresses cell survival, angiogenesis and vasculogenic mimicry of pancreatic ductal adenocarcinoma via disrupting the YAP-TEAD complex. Cancer Sci 108:478\u2013487. https:\/\/doi.org\/10.1111\/cas.13138","journal-title":"Cancer Sci"},{"key":"4299_CR70","doi-asserted-by":"publisher","first-page":"7602","DOI":"10.1038\/s41598-017-07632-8","volume":"7","author":"A Al-Moujahed","year":"2017","unstructured":"Al-Moujahed A, Brodowska K, Stryjewski TP, Efstathiou NE, Vasilikos I, Cichy J, Miller JW, Gragoudas E, Vavvas DG (2017) Verteporfin inhibits growth of human glioma in vitro without light activation. Sci Rep 7:7602. https:\/\/doi.org\/10.1038\/s41598-017-07632-8","journal-title":"Sci Rep"},{"key":"4299_CR71","doi-asserted-by":"publisher","first-page":"1","DOI":"10.7150\/jca.27472","volume":"10","author":"JW Lui","year":"2019","unstructured":"Lui JW, Xiao S, Ogomori K, Hammarstedt JE, Little EC, Lang D (2019) The efficiency of verteporfin as a therapeutic option in pre-clinical models of melanoma. J Cancer 10:1\u201310. https:\/\/doi.org\/10.7150\/jca.27472","journal-title":"J Cancer"},{"key":"4299_CR72","doi-asserted-by":"publisher","first-page":"110257","DOI":"10.18632\/oncotarget.22628","volume":"8","author":"ML Fisher","year":"2017","unstructured":"Fisher ML, Grun D, Adhikary G, Xu W, Eckert RL (2017) Inhibition of YAP function overcomes BRAF inhibitor resistance in melanoma cancer stem cells. Oncotarget 8:110257\u2013110272. https:\/\/doi.org\/10.18632\/oncotarget.22628","journal-title":"Oncotarget"},{"key":"4299_CR73","doi-asserted-by":"publisher","first-page":"2663","DOI":"10.1111\/jcmm.13182","volume":"21","author":"W-Q Zhang","year":"2017","unstructured":"Zhang W-Q, Dai Y-Y, Hsu P-C, Wang H, Cheng L, Yang Y-L, Wang Y-C, Xu Z-D, Liu S, Chan G, Hu B, Li H, Jablons DM, You L (2017) Targeting YAP in malignant pleural mesothelioma. J Cell Mol Med 21:2663\u20132676. https:\/\/doi.org\/10.1111\/jcmm.13182","journal-title":"J Cell Mol Med"},{"key":"4299_CR74","unstructured":"Dwivedi N, Sinha S, Wallace DP, Calvet JP, Rao R (2018) Cystic epithelial cells modify their microenvironment to promote fibrosis in polycystic kidney disease. J Am Soc Nephrol Kidney Week 2018 Abstract Supplement p 30, TH-OR106. Available https:\/\/www.asn-online.org\/api\/download\/?file=\/education\/kidneyweek\/archives\/KW18Abstracts.pdf . Accessed June 2019"},{"key":"4299_CR75","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1681\/ASN.2013121312","volume":"26","author":"K Hopp","year":"2015","unstructured":"Hopp K, Hommerding CJ, Wang X, Ye H, Harris PC, Torres VE (2015) Tolvaptan plus pasireotide shows enhanced efficacy in a PKD1 model. J Am Soc Nephrol 26:39\u201347. https:\/\/doi.org\/10.1681\/ASN.2013121312","journal-title":"J Am Soc Nephrol"},{"key":"4299_CR76","doi-asserted-by":"publisher","first-page":"1171","DOI":"10.2174\/0929867323666160316125048","volume":"23","author":"F Gibault","year":"2016","unstructured":"Gibault F, Corvaisier M, Bailly F, Huet G, Melnyk P, Cotelle P (2016) Non-Photoinduced biological properties of verteporfin. Curr Med Chem 23:1171\u20131184","journal-title":"Curr Med Chem"},{"key":"4299_CR77","doi-asserted-by":"publisher","first-page":"2076","DOI":"10.1016\/j.str.2015.09.009","volume":"23","author":"AV Pobbati","year":"2015","unstructured":"Pobbati AV, Han X, Hung AW, Weiguang S, Huda N, Chen G-Y, Kang C, Chia CSB, Luo X, Hong W, Poulsen A (2015) Targeting the central pocket in human transcription factor TEAD as a potential cancer therapeutic strategy. Structure 23:2076\u20132086. https:\/\/doi.org\/10.1016\/j.str.2015.09.009","journal-title":"Structure"},{"issue":"3","key":"4299_CR78","doi-asserted-by":"publisher","first-page":"1291","DOI":"10.1021\/acs.jmedchem.8b01402","volume":"62","author":"Sarah A. Smith","year":"2019","unstructured":"Smith SA, Sessions RB, Shoemark DK, Williams C, Ebrahimighaei R, McNeill MC, Crump MP, McKay TR, Harris G, Newby AC, Bond M (2019) Antiproliferative and antimigratory effects of a novel YAP-TEAD interaction inhibitor identified using in silico molecular docking. J Med Chem. https:\/\/doi.org\/10.1021\/acs.jmedchem.8b01402","journal-title":"Journal of Medicinal Chemistry"},{"key":"4299_CR79","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1038\/s41420-018-0124-8","volume":"4","author":"Y-W Li","year":"2018","unstructured":"Li Y-W, Xu J, Zhu G-Y, Huang Z-J, Lu Y, Li X-Q, Wang N, Zhang F-X (2018) Apigenin suppresses the stem cell-like properties of triple-negative breast cancer cells by inhibiting YAP\/TAZ activity. Cell Death Discov 4:105. https:\/\/doi.org\/10.1038\/s41420-018-0124-8","journal-title":"Cell Death Discov"},{"key":"4299_CR80","first-page":"709","volume":"11","author":"Y Shi","year":"2019","unstructured":"Shi Y, Cao T, Sun Y, Xia J, Wang P, Ma J (2019) Nitidine chloride inhibits cell proliferation and invasion via downregulation of YAP expression in prostate cancer cells. Am J Transl Res 11:709\u2013720","journal-title":"Am J Transl Res"},{"key":"4299_CR81","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/j.ejca.2018.05.013","volume":"99","author":"G Rao","year":"2018","unstructured":"Rao G, Kim I-K, Conforti F, Liu J, Zhang Y-W, Giaccone G (2018) Dasatinib sensitises KRAS-mutant cancer cells to mitogen-activated protein kinase kinase inhibitor via inhibition of TAZ activity. Eur J Cancer 99:37\u201348. https:\/\/doi.org\/10.1016\/j.ejca.2018.05.013","journal-title":"Eur J Cancer"},{"key":"4299_CR82","doi-asserted-by":"publisher","first-page":"3471","DOI":"10.21873\/anticanres.12617","volume":"38","author":"Y Oku","year":"2018","unstructured":"Oku Y, Nishiya N, Sugiyama S, Sato H, Uehara Y (2018) Sensitisation of cancer cells to MLN8237, an Aurora-A inhibitor, by YAP\/TAZ inactivation. Anticancer Res 38:3471\u20133476. https:\/\/doi.org\/10.21873\/anticanres.12617","journal-title":"Anticancer Res"},{"key":"4299_CR83","doi-asserted-by":"publisher","first-page":"3192","DOI":"10.3892\/ol.2017.7672","volume":"15","author":"M Zhou","year":"2018","unstructured":"Zhou M, Zhang Y, Wei H, He J, Wang D, Chen B, Zeng J, Gong A, Xu M (2018) Furin inhibitor D6R suppresses epithelial-mesenchymal transition in SW1990 and PaTu8988 cells via the Hippo-YAP signaling pathway. Oncol Lett 15:3192\u20133196. https:\/\/doi.org\/10.3892\/ol.2017.7672","journal-title":"Oncol Lett"},{"key":"4299_CR84","doi-asserted-by":"publisher","first-page":"188","DOI":"10.5527\/wjn.v6.i4.188","volume":"6","author":"WE Sweeney","year":"2017","unstructured":"Sweeney WE, Frost P, Avner ED (2017) Tesevatinib ameliorates progression of polycystic kidney disease in rodent models of autosomal recessive polycystic kidney disease. World J Nephrol 6:188\u2013200. https:\/\/doi.org\/10.5527\/wjn.v6.i4.188","journal-title":"World J Nephrol"},{"key":"4299_CR85","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1046\/j.1523-1755.2000.00829.x","volume":"57","author":"WE Sweeney","year":"2000","unstructured":"Sweeney WE, Chen Y, Nakanishi K, Frost P, Avner ED (2000) Treatment of polycystic kidney disease with a novel tyrosine kinase inhibitor. Kidney Int 57:33\u201340. https:\/\/doi.org\/10.1046\/j.1523-1755.2000.00829.x","journal-title":"Kidney Int"},{"key":"4299_CR86","doi-asserted-by":"publisher","first-page":"889","DOI":"10.2215\/CJN.08350813","volume":"9","author":"MA Cadnapaphornchai","year":"2014","unstructured":"Cadnapaphornchai MA, George DM, McFann K, Wang W, Gitomer B, Strain JD, Schrier RW (2014) Effect of pravastatin on total kidney volume, left ventricular mass index, and microalbuminuria in pediatric autosomal dominant polycystic kidney disease. Clin J Am Soc Nephrol 9:889\u2013896. https:\/\/doi.org\/10.2215\/CJN.08350813","journal-title":"Clin J Am Soc Nephrol"},{"key":"4299_CR87","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1038\/ncb2936","volume":"16","author":"G Sorrentino","year":"2014","unstructured":"Sorrentino G, Ruggeri N, Specchia V, Cordenonsi M, Mano M, Dupont S, Manfrin A, Ingallina E, Sommaggio R, Piazza S, Rosato A, Piccolo S, Del Sal G (2014) Metabolic control of YAP and TAZ by the mevalonate pathway. Nat Cell Biol 16:357\u2013366. https:\/\/doi.org\/10.1038\/ncb2936","journal-title":"Nat Cell Biol"},{"key":"4299_CR88","doi-asserted-by":"publisher","first-page":"542","DOI":"10.1016\/j.fob.2015.06.007","volume":"5","author":"Y Oku","year":"2015","unstructured":"Oku Y, Nishiya N, Shito T, Yamamoto R, Yamamoto Y, Oyama C, Uehara Y (2015) Small molecules inhibiting the nuclear localization of YAP\/TAZ for chemotherapeutics and chemosensitizers against breast cancers. FEBS Open Bio 5:542\u2013549. https:\/\/doi.org\/10.1016\/j.fob.2015.06.007","journal-title":"FEBS Open Bio"}],"container-title":["Pediatric Nephrology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00467-019-04299-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00467-019-04299-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00467-019-04299-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,23]],"date-time":"2022-09-23T14:26:56Z","timestamp":1663943216000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00467-019-04299-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,7,11]]},"references-count":88,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2020,7]]}},"alternative-id":["4299"],"URL":"https:\/\/doi.org\/10.1007\/s00467-019-04299-3","relation":{},"ISSN":["0931-041X","1432-198X"],"issn-type":[{"value":"0931-041X","type":"print"},{"value":"1432-198X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,7,11]]},"assertion":[{"value":"1 May 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 June 2019","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 June 2019","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 July 2019","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"R.-U.M. received honoraria for counselling and scientific lectures and the Dept. II of Internal Medicine was supported by research funding from Otsuka Pharmaceutical.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}